Lv1
16 积分 2023-11-09 加入
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
7小时前
待确认
Neladalkib (NVL-655), a highly selective anaplastic lymphoma kinase (ALK) inhibitor, compared to alectinib in first-line treatment of patients with ALK-positive advanced non-small cell lung cancer: The phase 3 ALKAZAR study
13小时前
求助中
ALK inhibitors against resistance in non-small cell lung cancer: an 18 year medical arms race
15小时前
已完结
The immunology of asthma
23天前
已完结
Anti-cytokine biologics for asthma in adults
23天前
已完结
Mitogen-activated protein kinases as therapeutic targets for asthma
4个月前
已完结
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
5个月前
已完结
Rational combinations of targeted cancer therapies: background, advances and challenges
5个月前
已完结
KMT9 Controls Stemness and Growth of Colorectal Cancer
8个月前
已完结
The dopamine transporter antagonist vanoxerine inhibits G9a and suppresses cancer stem cell functions in colon tumors
8个月前
已完结
Breathlessness in COPD: linking symptom clusters with brain activity
皖公网安备34019202002308
